Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) is unquestionably a darkhorse among giants operating in the emerging South American cannabis scene. At a non-diluted market cap of under $50 million and scant revenues to date, the company’s profile has yet to go mainstream. But from my vantage point, Khiron is positioning itself as the ideal takeover candidate for a senior LP looking for licensing and proximity to the lucrative Latin American market. We look under the hood and examine this thesis further.
Unless you’re a die-hard cannabis aficionado or early stage investor, you may be unaware of what Khiron Life Sciences does. To summarize: the company is a vertically-integrated medical cannabis company with its core operations in Colombia. Its primary focus is set on the 50 million-strong Colombian market, in which Khiron estimates approximately 5.6 million patients may qualify for its services. As an early trailblazer in the local market, Khiron has already established several seed-to-patient pathways which few North American entrants can boast.
In fact, Khiron is only one of two companies currently registered by the Colombian Agricultural Institute (ICA) as an agronomical unit—a mandatory requirement for commercializing medical cannabis products in Colombia for distribution. This milestone positions Khiron to receive the first allocation of quota to commence commercial cultivation of high THC strains and CBD strains which don’t require quota. In conjunction with additional licences procured from the Ministry of Justice in Colombia in October 2017, Khiron Colombia is now fully approved to cultivate, produce, distribute domestically and export internationally both tetrahydrocannabinol and cannabidiol medicinal cannabis.
Aside from the company’s ready-to-go licensing capabilities, its growing patient portfolio should be an attractive asset to acquirer companies.
Just today, the company announced a Letter of Intent to acquire Colombia’s leading health network, otherwise known as the Latin American Institute of Neurology and the Nervous System (ILANS). ILANS represents an estimated 100,000 patients and has two established neurological clinics located in Bogota. Included in the package are 46 physicians from various disciplines, and direct distribution channel to ILANS existing client base. The deal provide an accretive source of revenue, and is EBITDA positive as per end-of-year (2017) audited financial results.
CEO Alvaro Torres discusses securing multiple medical cannabis endorsements from the two largest medical associations in Colombia
For acquiring companies where networking is a key consideration, Khiron has those bases covered too.
On July 17th, the company announced that former Mexican president Vicente Fox Quesada had been added to its board of directors, effective immediately. Obviously, the high-profile appointment puts Khiron in a strong position to expedite expansion plans in other key Latin American markets—particularly Mexico. No other Canadian LP, to my knowledge, has that kind of ultra-heavyweight Rolodex at their disposal.
Presumably, it’s one that carries an incalculable and implicit value-add other LPs would love to secure.
Big Cannabis Is Already Expanding in Latin America—Who’s Next?
Another attractive Khiron feature is its very affordable price tag. Its market capitalization is such that even if acquired at a hefty premium, it’s purchase price would be little more than a rounding error on some major LP’s balance sheet.
The company has a non-diluted market cap of about $48 million at the present time. Including the acquisition of ILANS—which includes a share-based payment totaling $2.1 million based on its 20-day exchange VWAP—Khiron’s fully-diluted market cap is only around $70 million. That kind of expenditure is something even mid-major Canadian LPs could afford, should landing a Latin American beachhead fit within the operating model.
And why wouldn’t it? With a total population of around 620 million people and 68 million patients, Latin America provides huge early-stage growth potential for LP looking to expand internationally. Big cannabis is already beginning to make its move.
In July, Canopy Growth Corp. unveiled a new subsidiary called Canopy LATAM Corp. to exploit cannabis liberalization in the region. Included in the newly-minted Canopy LATAM unit are the assets of Spectrum Cannabis Colombia S.A.S., which was formerly known as Colombian Cannabis S.A.S. The deal could be worth $96 million in Canopy Growth stock if all acquirer milestones are met.
Aphria Inc. recently entered the fray as well. On July 17th, the company inked a $193 million deal with Scythian Biosciences Corp. which netted them significant Caribbean and Latin American assets—including 90% of Colcanna S.A.S., a Colombian medical cannabis producer, currently licensed for cultivation and importation of CBD, extraction, production, research and exportation of medical cannabis products. Also procured was optionality to purchase 50.1% of a Brazilian incorporated entity Scythian is seeking to acquire, giving Aphria a potential segue into the 200-million strong Brazilian cannabis market. The deal will largely depend on whether the said entity procures a applied-for medical cannabis cultivation, processing and distribution license in Brazil.
Notably lagging in Latin American assets among the large Canadian LPs is Aurora Cannabis Inc., which owns the world’s largest medical cannabis portfolio after finalizing the MedReleaf Corp. acquisition in late July. Presumably, staking a considerable Latin America presence will be on the company’s radar at some relatively near point in time—even if that time isn’t necessary now. Aurora already competes heavily with Canopy and Aphria in both the European and Australian markets. It’s hard to envision they neglect Latin America for too much longer.
Given Aurora’s penchant for acquiring assets rather over building them organically, Khiron Life Sciences might provide an affordable segue option in Latin America. One that gives them not just a cultivation presence, but a revenue-generating patient portfolio as well.
From my perspective, Khiron is amassing a portfolio of assets which should make it an attractive takeover target for an acquiring company looking to make splash in Latin America. The company has its licensing ducks in a row, requisite cultivation/land package/greenhouses, growing patient networks, and high-level BOD contacts which give the company a material competitive advantage. All these assets come at a very reasonable price tag, based on Khiron’s current market capitalization.
While the company is more of a regional (Colombian) player at the moment, it has the most distinguished presence in Colombia and provides an ideal beachhead into the South American, and potentially, Mexican markets.
Whether Aurora Cannabis or some other major LP will take the bait I cannot say. I’m simply using my spider sense which has served me well as a Midas Letter analyst. Regardless, it should be a possibility worth considering, given Khiron’s top line attractiveness and recent foray by Canopy Growth and Aphria down south.
**IMPORTANT! BY VIEWING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
Notice for Forward-Looking Information
Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.
Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to KHIRON’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by KHIRON $100,000 per month for one year as of May 15, 2019 for a newsletter campaign and certain banner ads, of which a portion is spent to produce multi-media content and a portion to the advertising budget targeting investor. In addition, the Company owns 150,000 Restricted Share Units (RSU’s) of KHIRON, and will benefit from its price appreciation. This compensation and our rights ownership in KHIRON is a major conflict with our ability to be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by KHIRON to conduct investor awareness advertising and marketing for KHIRON. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.
SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter owns Restricted Share Units of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR. The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.